nach oben

The European Journal of Health Economics

Erschienen in:

01.06.2013 | Original Paper

How to use pharmacy claims data to measure patient nonadherence? The example of oral diabetics in therapy of type 2 diabetes mellitus

verfasst von: Thomas Wilke, Antje Groth, Sabrina Mueller, Dallas Reese, Roland Linder, Susanne Ahrens, Frank Verheyen

Erschienen in: The European Journal of Health Economics | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The purpose of this study was to describe the methodological framework underlying nonadherence (NA) measurement based on pharmacy claims data, its quantitative impact on the results of NA studies, and to identify those methodological categories most likely to explain diabetes-related clinical outcomes. We use the example of oral antidiabetics in the treatment of diabetes mellitus type 2; 113,108 patients derived from a German statutory health insurance fund were analyzed.

Methods

We identified 12 methodological categories as pervasive features in pharmacy claims data based NA analyses. The influence of the different methodological categories and their parameters on analysis results was tested using sensitivity analysis. To validate alternative methodological framework options, we performed multivariate logistical regression estimates using diabetes-related hospitalization/clinical events as a combined dichotomized dependent variable.

Results

The choice of parameters within the identified 12 methodological categories available has exceptional impact on the results of pharmacy data based claims NA analyses. When the full range of theoretically possible cases is considered in our sample, it can be seen that the resulting NA range is between 15.7 % and 97.0 %. The definition of the required daily dose, the decision to use either a prescription-/interval-based approach, and the classes of medication analyzed exert a notable influence on the study results. In our analysis, 69.4 % of the 216 different study design options analyzed significantly explain the likelihood of diabetes-related clinical events.

Conclusions

We recommend strongly that methodological transparency is awarded a much more important role in the conduct of NA analyses made on the basis of pharmacy claims data.

Nur mit Berechtigung zugänglich

Search strings were diabetes, oral agents, administrative database, diabetes oral agents secondary data, diabetes oral agents, medication possession ratio, and diabetes oral agents proportion of days covered.

A10BA (Biguanides), A10BB/A10BC (Sulfonamides), A10BF (Alpha-glucosidase-inhibitors), A10BG (Thiazolidinediones), A10BH (Dipeptidyl-peptidase-4-inhibitors), and A10BX (other blood glucose lowering drugs).

Cases 18, 22, 52, 60, 64, 66, 70, 72, 138, 142, 164, 200, 211, 212, 216.

Haynes, R.B., Taylor, D.W., Sacket, D.L., et al.: Can simple clinical measurements detect patient noncompliance. Hypertension 2(6), 757–764 (1980)PubMedCrossRef

Osterberg, L., Blaschke, T.: Adherence to medication. N. Engl. J. Med. 353(5), 487–497 (2005)PubMedCrossRef

Cramer, J.A., Roy, A., Burrell, A., et al.: Medication compliance and persistence: terminology and definitions. Value Health 11(1), 44–47 (2008)PubMedCrossRef

Simpson, S.H., Eurich, D.T., Majumdar, S.R., et al.: A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 333(7557), 18–19 (2006)CrossRef

Salas, M., Hughes, D., Zuluaga, A., et al.: Cost of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health 12(6), 915–922 (2009)PubMedCrossRef

Gorenoi, V., Schönermark, M.P., Hagen, A.: HTA-Bericht 65. Maßnahmen zur Verbesserung der Compliance bzw. Adherence in der Arzneimitteltherapie mit Hinblick auf den Therapieerfolg. Köln, Deutsches Institut für Medizinische Dokumentation und Information (DIMDI) (2007)

Cramer, J.A.: A systematic review of adherence with medications for diabetes. Diabetes Care 27(5), 1218–1224 (2004)PubMedCrossRef

Cramer, J.A., Benedict, A., Muszbek, N., Khan, Z.M.: The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidemia: a review. Int. J. Clin. Pract. 62(1), 76–87 (2008)PubMedCrossRef

Haynes, R.B., Ackloo, E., Sahota, N., et al.: Interventions for enhancing medication adherence. The Cochrane Database Syst. Rev. 2, CD000011 (2008)

10.

World Health Organization: adherence to long-term therapies. WHO Library Cataloguing-in-Publication Data. (2003)

11.

Ho, P.M., Rumsfeld, J.S., Masoudi, F.A., McClure, D.L., et al.: Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch. Intern. Med. 166, 1836–1841 (2006)PubMedCrossRef

12.

Morris, A.D., Boyle, D.I.R., McMahon, A.D., Greene, S.A., et al.: Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. Lancet 350(22), 1505–1510 (1997)PubMedCrossRef

13.

White, T.J., Vanderplas, A., Chang, E., Dezii, C.M., Abrams, G.D.: The cost of nonadherence to oral antihyperglycemic medication in individuals with diabetes mellitus and concomitant diabetes mellitus and cardiovascular disease in a managed care environment. Disease manag. health outcomes 12(3), 181–188 (2004)CrossRef

14.

Haynes, R.B., McDonald, H.P., Garg, A.X.: Helping patients follow prescribed treatment. JAMA 288(22), 2880–2883 (2002)PubMedCrossRef

15.

Sikka, R., Xia, F., Aubert, R.E.: Estimating medication persistency using administrative claims data. Am. J. Manag. Care 11(7), 449–457 (2005)PubMed

16.

Peterson, A.M., Nau, D.P., Cramer, J.A., Benner, J., et al.: A checklist for medication compliance and persistence studies using retrospective databases. Value Health 10(1), 3–12 (2007)PubMedCrossRef

17.

Choo, P.W., Rand, C.S., Inui, T.S., et al.: Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med. Care 37(9), 846–857 (1999)PubMedCrossRef

18.

Rickles, N.M., Svarstad, B.L.: Relationships between multiple self-reported nonadherence measures and pharmacy records. Res. Soc. Adm. Pharm. 3(4), 363–377 (2007)CrossRef

19.

Grymonpre, R., Cheang, M., Fraser, M., Metge, C., Sitar, D.: Validity of a prescription claims database to estimate medication adherence in older persons. Med. Care 44(5), 471–477 (2006)PubMedCrossRef

20.

Pollack, M., Chastek, B., Williams, S.A., Moran, J.: Impact of treatment complexity on adherence and glycemic control: an analysis of oral antidiabetic agents. JCOM 17(6), 257–265 (2010)

21.

Lawrence, D.B., Ragucci, K.R., Long, L.B., Parris, B.S., Helfer, L.A.: Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c attainment for HMO patients enrolled in a diabetes disease management program. J. Manag. Care Pharm. 12(6), 466–471 (2006)PubMed

22.

Pladeval, M., Williams, L.K., Potts, L.A., et al.: Clinical outcomes and adherence to amedications measured by claims data in patients with diabetes. Diabetes Care 27(12), 2800–2805 (2004)CrossRef

23.

Spoelstra, J.A., Stolk, R.P., Heerdink, E.R., Klungel, O.H., et al.: Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy? Pharmacoepidemiol. Drug Saf. 12, 121–127 (2003)PubMedCrossRef

24.

Yu, A.P., Yu, Y.F., Nichol, M.B.: Estimating the effect of medication adherence on health outcomes among patients with type 2 diabetes—an application of marginal structural models. Value Health 13(8), 1038–1045 (2010)PubMedCrossRef

25.

Gibson, T.B., Song, X., Alemayehu, B., Wang, S.S., Waddell, J.L., et al.: Cost sharing, adherence, and health outcomes in patients with diabetes. Am. J. Manag. Care 16(8), 589–600 (2010)PubMed

26.

Karve, S., Cleves, M.A., Helm, M., Hudson, T.J., et al.: An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med. Care 46(11), 1125–1133 (2008)PubMedCrossRef

27.

Hansen, R.A., Dusetzina, S.B., Dominik, R.C., Gaynes, B.N.: Prescription refill records as a screening tool to identify antidepressant non-adherence. Pharmacoepidemiol. Drug Saf. 19, 33–37 (2010)PubMedCrossRef

28.

Ciechanowski, P.S., Katon, W.J., Russo, J.E.: Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch. Intern. Med. 160, 3278–3285 (2000)PubMedCrossRef

29.

Hess, L.M., Raebel, M.A., Conner, D.A., Malone, D.C.: Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann. Pharmacother. 40, 1280–1288 (2006)PubMedCrossRef

30.

Dezii, C.M., Kawabata, H., Tran, M.: Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South. Med. J. 95(1), 68–71 (2002)PubMed

31.

Andrade, S.E., Kahler, K.H., Frech, F., Chan, K.A.: Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol. Drug Saf. 15, 565–574 (2006)PubMedCrossRef

32.

Caetano, P.A., Lam, J., Morgan, S.G.: Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin. Ther. 28(9), 1411–1424 (2006)PubMedCrossRef

33.

Steiner, J.F., Prochazka, A.V.: The assessment of refill compliance using pharmacy records: methods, validity, and applications. J. Clin. Epidemiol. 50(1), 105–116 (1997)PubMedCrossRef

34.

Martin, B.C., Wiley-Exley, E.K., Richards, S., Domino, M.E., et al.: Contrasting measures of adherence with simple drug use, medication switching and therapeutic duplication. Ann. Pharmacother. 43(1), 36–44 (2009)PubMedCrossRef

35.

Choudry, N.K., Shrank, W.H., Levin, R.L., Lee, J.L., et al.: Measuring concurrent adherence to multiple related medications. Am. J. Manag. Care 15(7), 457–464 (2009)

36.

Vink, N.M., Klungel, O.H., Stolk, R.P., Denig, P.: Comparison of various measures for assessing medication refill adherence using prescription data. Pharmacoepidemiol. Drug Saf. 18, 159–165 (2009)PubMedCrossRef

37.

Yeaw, J., Benner, J.S., Walt, J.G., Sian, S., Smith, D.B.: Comparing adherence and persistence across 6 chronic medication classes. J. Manag. Care Pharm. 15(9), 728–740 (2009)PubMed

38.

Bryson, C.L., Au, D.H., Young, B., McDonell, M.B., Fihn, S.D.: A refill adherence algorithm for multiple short intervals to estimate refill compliance (ReComp). Med. Care 45(6), 497–504 (2007)PubMedCrossRef

39.

Duru, O.K., Schmittdiel, J.A., Dyer, W.T., Parker, M.M., et al.: Mail-order pharmacy use and adherence to diabetes-related medications. Am. J. Manag. Care 16(1), 33–40 (2010)PubMed

40.

Karve, S., Cleves, M.A., Helm, M., Hudson, T.J., West, D.S., Martin, B.C.: Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr. Med. Res. Opin. 25(9), 2303–2310 (2009)PubMedCrossRef

41.

Sclar, D.A., Robison, L.M., Skaer, T.L., Dickson, W.M., Kozma, C.M., Reeder, C.E.: Sulfonylurea pharmacotherapy regimen adherence in a medicaid population: influence of age, gender, and race. Diabetes Educ. 25(4), 531–532 (1999)PubMedCrossRef

42.

Venturini, F., Nichol, M.B., Sung, J.C., Bailey, K.L., Cody, M., McCombs, J.S.: Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-based study. Ann. Pharmacother. 33(3), 281–288 (1999)PubMedCrossRef

43.

Brown, J.B., Nichols, G.A., Glauber, H.S., Bakst, A.: Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus. Clin. Ther. 21(6), 1045–1057 (1999)PubMedCrossRef

44.

Dailey, G., Kim, M.S., Lian, J.F.: Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin. Ther. 23(8), 1311–1320 (2001)PubMedCrossRef

45.

Boccuzzi, S.J., Wogen, J., Fox, J., Sung, J.C., Shah, A.B., Kim, J.: Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care 24(8), 1411–1415 (2001)PubMedCrossRef

46.

Catalan, V.S., Couture, J.A., LeLorier, J.: Predictors of persistence of use of the novel antidiabetic agent acarbose. Arch. Intern. Med. 161, 1106–1112 (2001)PubMedCrossRef

47.

Morningstar, B.A., Sketris, I.S., Kephart, G.C., Sclar, D.A.: Variation in pharmacy prescription refill adherence measures by type of oral antihyperglycaemic drug therapy in seniors in Nova Scotia, Canada. J. Clin. Pharm. Ther. 27(3), 213–220 (2002)PubMedCrossRef

48.

Melikian, C., White, T.J., Vanderplas, A., Dezii, C.M., Chang, E.: Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin. Ther. 24(3), 460–467 (2002)PubMedCrossRef

49.

Schectman, J.M., Nadkarni, M.M., Voss, J.D.: The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care 25(6), 1015–1021 (2002)PubMedCrossRef

50.

Evans, J.M., Donnan, P.T., Morris, A.D.: Adherence to oral hypoglycaemic agents prior to insulin therapy in type 2 diabetes. Diabet. Med. 19(8), 685–688 (2002)PubMedCrossRef

51.

Donnan, P.T., MacDonald, T.M., Morris, A.D.: Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet. Med. 19(4), 279–284 (2002)PubMedCrossRef

52.

Vanderpoel, D.R., Hussein, M.A., Watson-Heidari, T., Perry, A.: Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin. Ther. 26(12), 2066–2075 (2004)PubMedCrossRef

53.

Lau, D.T., Nau, D.P.: Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 27(9), 2149–2153 (2004)PubMedCrossRef

54.

Hepke, K.L., Martus, M.T., Share, D.A.: Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am. J.Manag. Care 10, 144–151 (2004)PubMed

55.

Nau, D.P., Chao, J., Aikens, J.E.: The relationship of guideline-concordant depression treatment and patient adherence to oral diabetes medications. Res. Soc. Adm. Pharm. 1(3), 378–388 (2005)CrossRef

56.

Leblond, J., Pilon, D., Beaudette, C.P., Maheux, P.: Predictors of non persistence with Thiazolidinediones in patients with type 2 diabetes. Can. J.Diabetes 29(2), 95–101 (2005)

57.

Doró, P., Benko, R., Kosik, E., Matuz, M., Tóth, K., Soós, G.: Utilization of oral antihyperglycemic drugs over a 7-year period (1998–2004) in a Hungarian population and adherence to drug therapy. Eur. J. Clin. Pharmacol. 61(12), 893–897 (2005)PubMedCrossRef

58.

Hertz, R.P., Unger, A.N., Lustik, M.B.: Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin. Ther. 27(7), 1064–1073 (2005)PubMedCrossRef

59.

Willey, C.J., Andrade, S.E., Cohen, J., Fuller, J.C., Gurwitz, J.H.: Polypharmacy with oral antidiabetic agents: an indicator of poor glycemic control. Am. J. Manag. Care 12(8), 435–440 (2006)PubMed

60.

Kalsekar, I.D., Madhavan, S.S., Amonkar, M.M., Makela, E.H., Scott, V.G., Douglas, S.M., Elswick, B.L.: Depression in patients with type 2 dibetes: impact on adherence to oral hypoglycemic agents. Ann. Pharmacother. 40(4), 605–611 (2006)PubMedCrossRef

61.

Shenolikar, R.A., Balkrishnan, R., Camacho, F.T., Whitmire, J.T., Anderson, R.T.: Race and medication adherence in medicaid enrollees with type-2 diabetes. J. Natl Med. Assoc. 98(7), 1071–1077 (2006)PubMed

62.

Brixner, D.I., Joish, V.N., Odera, G.M., Avey, S.G., Hanson, D.M., Cannon, H.E.: Effects of benefit design change across 5 disease states. Am. J. Manag. Care 13(6), 370–376 (2007)PubMed

63.

Kalsekar, I., Sheehan, C., Peak, A.: Utilization patterns and medication adherence in patients with type 2 diabetes: variations based on type of pharmacy (chain vs independent). Res. Soc. Adm. Pharm. 3(4), 378–391 (2007)CrossRef

64.

Briesacher, B.A., Andrade, S.E., Fouayzi, H., Chan, K.A.: Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 28(49), 437–443 (2008)PubMedCrossRef

65.

Cheong, C., Barner, J.C., Lawson, K.A., Johnsrud, M.T.: Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas medicaid recipients recipients. Clin. Ther. 30(10), 1893–1907 (2008)PubMedCrossRef

66.

Pan, F., Chernew, M.E., Fendrick, A.M.: Impact of fixed-dose combination drugs on adherence to prescription medications. J. Gen. Intern. Med. 23(5), 611–614 (2008)PubMedCrossRef

67.

Karter, A.J., Parker, M.M., Moffet, H.H., Ahmed, A.T., Schmittdiel, J.A., Selby, J.V.: New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv. Res. 44(5), 1640–1661 (2009)PubMedCrossRef

68.

Briesacher, B.A., Andrade, S.E., Fouayzi, H., Chan, K.A.: Medication adherence and the use of generic drug therapies. Am. J. Manag. Care 15(7), 450–456 (2009)PubMed

69.

Trinacty, C.M., Adams, A.S., Soumerai, S.B., Zhang, F., Meigs, J.B., Piette, J.D., Ross-Degnan, D.: Racial differences in long-term adherence to oral antidiabetic drug therapy: a longitudinal cohort study. BMC Health Serv. Res. 9, 24 (2009)PubMedCrossRef

70.

Haupt, D., Weitoft, G.R., Nilsson, J.L.: Refill adherence to oral antihyperglycaemic drugs in Sweden. Acta Diabetol. 46(3), 203–208 (2009)PubMedCrossRef

71.

Yang, Y., Thumula, V., Pace, P.F., Banahan 3rd, B.F., Wilkin, N.E., Lobb, W.B.: Predictors of medication nonadherence among patients with diabetes in medicare part D programs: a retrospective cohort study. Clin. Ther. 31(10), 2178–2188 (2009)PubMedCrossRef

72.

Kreyenbuhl, J., Dixon, L.B., McCarthy, J.F., Soliman, S., Ignacio, R.V., Valenstein, M.: Does adherence to medications for type 2 diabetes differ between individuals with vs without schizophrenia? Schizophr Bull 36(2), 428–435 (2010)PubMedCrossRef

73.

Hansen, R.A., Farley, J.F., Droege, M., Maciejewski, M.L.: A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005. Clin. Ther. 32(7), 1308–1319 (2010)PubMedCrossRef

Titel: How to use pharmacy claims data to measure patient nonadherence? The example of oral diabetics in therapy of type 2 diabetes mellitus
verfasst von: Thomas Wilke
Antje Groth
Sabrina Mueller
Dallas Reese
Roland Linder
Susanne Ahrens
Frank Verheyen
Publikationsdatum: 01.06.2013
Verlag: Springer-Verlag
Erschienen in: The European Journal of Health Economics / Ausgabe 3/2013
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-012-0410-y

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

How to use pharmacy claims data to measure patient nonadherence? The example of oral diabetics in therapy of type 2 diabetes mellitus

Abstract

Introduction

Methods

Results

Conclusions

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Spending more money, saving more lives? The relationship between avoidable mortality and healthcare spending in 14 countries

Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation—results for Canada, Italy, Sweden and Switzerland

Does the US health care safety net discourage private insurance coverage?

Terminal patients in Belgian nursing homes: a cost analysis

The impact of time cost of physical exercise on health outcomes by older adults: the DR’s EXTRA Study

Diffusion of innovations in social interaction systems. An agent-based model for the introduction of new drugs in markets